Warning: copy(/home/yu397326/vev.icu/www/image/cache/catalog/Product/Health/Colds and flu/Runny nose and sinuses/7715_Polydex _Runny nose and sinuses_buy_free_shipping-400x400.jpg): failed to open stream: Disk quota exceeded in /home/yu397326/vev.icu/www/catalog/model/tool/image.php on line 43 Polydex with phenylephrine nasal spray 15ml — Made in France — Free Delivery

Polydex with phenylephrine nasal spray 15ml — Made in France — Free Delivery

(Polydex )
Polydex with phenylephrine nasal spray 15ml — Made in France — Free Delivery
Availability: In Stock
Sophartex Brand: Sophartex

Pharmacological properties

Pharmacodynamic parameters. The combination of active pharmaceutical ingredients of the Polydex preparation determines its anti-inflammatory and antimicrobial effects against a wide range of gram-positive and gram-negative pathogens of infectious and inflammatory diseases of the cavity and paranasal sinuses; helps to reduce swelling of the mucous membrane and facilitate nasal breathing.

The synthetic glucocorticosteroid dexamethasone penetrates the cell membrane and binds with high affinity to specific cytoplasmic glucocorticoid receptors. This complex binds to DNA elements, which ultimately leads to a modification of transcription and, therefore, protein synthesis to achieve inhibition of leukocyte infiltration at the site of inflammation, interfere with the function of inflammatory response mediators, suppress humoral immune responses and reduce edema. The anti-inflammatory effect of dexamethasone involves the phospholipase A2 inhibiting proteins lipocortins, which control the biosynthesis of powerful inflammatory mediators such as prostaglandins and leukotrienes.

Neomycin is an aminoglycoside antibiotic isolated from cultures of Streptomyces fradiae. Its mechanism of action includes inhibition of protein synthesis by binding to the 30S subunit of the bacterial ribosome, as a result of which the bacterium cannot synthesize proteins vital for its growth. Neomycin can also inhibit bacterial DNA polymerase.

Neomycin is active against B. catarrhalis and Haemophilus influenzae, acinetobacteria, corynebacteria, causative agents of listeriosis, methicillin-susceptible staphylococcus, citrobacter, enterobacter, campylobacter, Escherichia coli, klebsiidellam, serummonellam, and morgansia.

Neomycin-resistant enterococci, streptococci, methicillin-resistant staphylococci, chlamydia, mycoplasma, rickettsia, P. stuartii, Pseudomonas aeruginosa, A. denitrificans, burkholderia, N. asteroides, flavobacteria, S. maltophilis.

Polymyxin B, a lipopeptide antibiotic isolated from Bacillus polymyxa, is bactericidal against gram-negative bacteria. The α- and γ-diaminobutyric acids of the positively charged polymyxin B form electrostatic interaction with the phosphate groups of the negatively charged lipid A on the outer membrane of the gram-negative bacterium. Calcium and magnesium ions are displaced from the phosphates of membrane lipids, destabilizing the lipopolysaccharide, which increases the permeability of the membrane and, as a result, leads to cell destruction. In addition, polymyxin B inhibits type II NADH-quinone oxidoreductase required for cellular respiration on the inner bacterial membrane, and can also bind and neutralize lipopolysaccharide released during bacterial lysis, preventing reactions to endotoxin.

Acinetobacteria, aeromonads, Alcaligenes spp. Are sensitive to polymyxin B. microorganisms of the genus Citrobacter, Enterobacter, Escherichia coli, Klebsiella, Moraxella, Pseudomonas aeruginosa, Salmonella, Shigella, S. maltophilia.

They show resistance to polymyxin B of Brucella, Burkholderia (B. cepacia, B. pseudomallei), Mycobacterium, B. catarrhalis, Campylobacter, Legionella, Morganella, Proteus, Neisseria, Serracias, Providence, C. meningosepticum, Cholerae and Vibrio Sharovidia rod-shaped spore-forming bacteria.

Phenylephrine is a sympathomimetic amine that acts predominantly on the α1-adrenergic receptors of the smooth muscle of the peripheral vascular wall. The vasoconstrictor effect of phenylephrine at the level of the mucous membrane of the nasal cavity and paranasal sinuses leads to a decrease in its swelling and improved drainage of the paranasal sinuses.

Pharmacokinetic parameters. Due to the insignificant absorption into the systemic circulation, the pharmacokinetic parameters of the preparation  have not been studied.


Pathology of the nasal cavity of an infectious and inflammatory nature (for example, acute sinusitis, acute rhinitis).


In each nasal passage 1 injection: adults - 3-5 times a day, children aged 15 years - 3 times a day. the duration of the course of therapy is on average 5 days. in the presence of manifestations of the disease after 10 days of therapy, the use of the preparation should be discontinued.

The preparation is injected as a spray by pressing on the bottle. At the time of injection, the bottle should be in an upright position, the patient's head should be slightly tilted forward.


Hypersensitivity to active pharmaceutical ingredients or other components of the preparation; the patient's stroke or the presence of risk factors for its development; ag (severe or poorly controlled); pronounced inconsistency of blood flow in the coronary arteries with the oxygen demand of the heart muscle; the assumption that the patient has glaucoma (angle-closure); the assumption of the impossibility of complete emptying of the bladder in the pathology of the prostate gland or the urethra; infection of herpes zoster, herpes simplex, varicella-zoster virus in the nose; convulsions (history); combined use with non-selective MAO inhibitors, any sympathomimetic agents or stimulants of α-adrenergic receptors; age under 15.

Side effects

Allergic reactions and sensitization to antibiotics in the composition of the preparation; palpitation, increased heart rate, myocardial infarction; acute attack of angle-closure glaucoma; vomiting, nausea, dry mouth; stroke, cerebralgia, convulsions; anxiety, agitation, behavioral disturbances, hallucinations, insomnia; increased body temperature; violation of urination (with urethroprostatic pathology), urinary retention; hyperhidrosis, itching, rashes, urticaria; ag (hypertensive crisis); dryness of the nasal mucosa.

Special instructions

You can not use it orally, and also increase the duration of the course or the dose of the preparation more than recommended (the likelihood of a systemic effect increases as a result of absorption of active ingredients).

The presence of GCS in the preparation can affect the symptoms of an allergic reaction.

Dexamethasone in the composition of the preparation can cause a positive reaction to a doping test.

If necessary, it can be used in combination with antibacterial agents with a systemic effect.

Combined use with other vasoconstrictor preparations increases the likelihood of overdose.

Do not use in patients with episodes of seizures or simultaneously with preparations that increase the likelihood of a convulsive reaction (preparations for local anesthesia, clobutinol, terpene derivatives, preparations containing atropine).

The presence of an active substance with a sympathomimetic effect requires strict adherence to the established course of therapy and the dose of the preparation, knowledge of information on contraindications.

Take with caution in patients with hyperthyroidism, ischemic heart disease, arterial hypertension.

Preparation therapy should be completed in case of nausea or adverse effects from the cardiovascular or nervous system.

Should not be used during pregnancy and lactation.


In the event that active substances enter the systemic circulation, the following options for preparation interactions are possible.

Phenylephrine cannot be combined with non-selective MAO inhibitors (up to 2 weeks after the end of therapy with the indicated agents), any sympathomimetic agents or stimulants of α-adrenergic receptors.

It is undesirable to combine phenylephrine with ergot alkaloids, selective and reversible MAO inhibitors, methylthioninium chloride.

Phenylephrine with halogenated volatile agents is used with caution for general anesthesia (if possible, stop using the preparation with phenylephrine a few days before surgery).

It is undesirable to combine dexamethasone with acetylsalicylic acid.

Use dexamethasone with aminoglutemide with caution; praziquantel; preparations that can cause arrhythmias like torsade de pointes or hypokalemia; digitalis preparations; anticonvulsants, inducers of the synthesis of metabolic enzymes in the liver.

Increased attention is needed in the combined use of dexamethasone with NSAIDs, acetylsalicylic acid; antihypertensive preparations; fluoroquinolone antibiotics, some macrolides (erythromycin, telithromycin and clarithromycin); nelfinavir and ritonavir-boosted protease inhibitors; some antimycotics (ketoconazole, voriconazole, itraconazole, posaconazole).


The development of systemic effects is possible, provided that the dose of the preparation is significantly exceeded or the duration of the course of therapy is longer than the recommended one.

Storage conditions

Out of the reach of children, at a temperature of ≤25 ° C.

Tags: Polydex

There are no reviews for this product.

Write a review

Buyers Online

Онлайн курсы IT